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Sulforaphane, a natural component 
of broccoli, inhibits vestibular 
schwannoma growth in vitro and  
in vivo
Bo Gyung Kim1, Takeshi Fujita2,3,4, Konstantina M. Stankovic3,4, D. Bradley Welling4, 
In Seok Moon5, Jae Young Choi5, Jieun Yun6, Jong Soon Kang6 & Jong Dae Lee1,3,4
Vestibular schwannoma (VS) is an intracranial tumor that causes significant morbidity, including 
hearing loss, tinnitus, dizziness, and possibly even death from brainstem compression. However, FDA-
approved pharmacologic treatments for VS do not exist. Sulforaphane (SFN) is a naturally occurring 
isothiocyanate found in cruciferous vegetables, such as broccoli, with potent chemoprotective effects  
in several cell types. Our objective was to determine whether SFN is effective against VS in vitro and  
in vivo. Human primary VS cells, HEI-193 schwannoma cells, and SC4 Nf2−/− Schwann cells were used to 
investigate the inhibitory effects of SFN in vitro. Cell proliferation was assessed by bromodeoxyuridine 
(BrdU) incorporation, and cell viability and metabolic activity was calculated by MTT assay. Apoptosis 
was measured by flow cytometry, terminal deoxynucleotidyl transferase-mediated dUTP nick end 
labeling (TUNEL) staining, and Western blot for cleaved caspases. A mouse model with a murine 
schwannoma allograft was also used to examine the antitumor activity of SFN. SFN exhibited 
significant antiproliferative activity in schwannoma cells in vitro, via the inhibition of HDAC activity 
and the activation of ERK. SFN treatment induced apoptosis and cell cycle arrest at the G2/M phase. 
SFN also significantly inhibited schwannoma growth in vivo. Our preclinical studies motivate a future 
prospective clinical study of SFN for the treatment of VS.
Vestibular schwannoma (VS) is a non-malignant tumor originating from Schwann cells of the vestibular nerve. 
VSs occur either sporadically and unilaterally, or bilaterally as hallmark tumors of neurofibromatosis type 2 
(NF2). VSs result in significant morbidity, including hearing loss, tinnitus and dizziness. As these tumors grow, 
they can cause facial paralysis and other cranial neuropathies, as well as death from brainstem compression. 
Although microsurgery and stereotactic radiation remain the mainstay of treatment for growing VSs, observation 
is an acceptable option for newly diagnosed and non-growing tumors. At present, since the majority of VSs are 
diagnosed early, observation is the most common initial choice1. Such a choice is justified because both microsur-
gery and stereotactic radiation therapy carry significant risks, including the risk of irreversible ipsilateral hearing 
loss. Despite the slow progression of the disease, no pharmacologic treatments have been approved for VS, high-
lighting the need to develop effective and well-tolerated pharmaceutical therapies.
Several clinical trials for NF2-associated VSs are currently underway, targeting key pathways important for 
disease pathogenesis2,3. However, these trials have relied on expensive chemotherapeutic agents with substan-
tial adverse effects, including cardiovascular toxicity4, so widespread use of these drugs to treat non-malignant 
tumors is unlikely. The unmet medical need to identify safe agents with minimal adverse effects to treat VS has 
motivated our study of dietary agents with potential anti-tumoral activities. Dietary agents found in fruit and veg-
etables have been shown to interfere with multiple cellular signaling pathways important in cancer pathogenesis, 
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and several of these agents are capable of not only preventing but even treating some cancers5. We focus on sulfo-
raphane, a dietary agent extracted from cruciferous vegetables, and its potential to inhibit VS growth.
Sulforaphane (SFN) is an isothiocyanate found in cruciferous vegetables, such as broccoli. SFN has been 
shown to exhibit chemoprotective effects for various tumors, including those of the prostate, lung, breast and 
colon, in vitro and in vivo6–8. These studies have shown that SFN significantly affects cell survival and leads to 
apoptosis through a variety of molecular mechanisms, including the potent inhibition of histone deacetylase 
(HDAC)9–11. As there have been no reports examining the effect of SFN on vestibular schwannoma, here we char-
acterize the ilnhibitory effects of SFN on VS cells in vitro using primary human VS cells and VS-derived cell lines, 
and in vivo using a mouse model with a murine schwannoma allograft.
Results
Sulforaphane inhibits the proliferation of primary human vestibular schwannoma cells and an 
NF2-derived cell line in vitro. After 48 hours of incubation with SFN (10 μ M), BrdU was used to assess 
proliferation in cells grown from three different primary human VSs, compared to untreated controls (Fig. 1A). 
SFN substantially and significantly (p < 0.001) reduced BrdU incorporation by primary VS cells, consistent with 
an anti-proliferative effect. This inhibitory effect of SFN was confirmed using two different cell lines and a differ-
ent assay. Specifically, human HEI-193 cells (Fig. 1B) and mouse SC4 cells (Fig. 1C) were treated with 5, 10, 15 or 
25 μ M of SFN or vehicle control (DMSO) for 48 hours, and cell viability was assessed using an MTT assay. SFN 
inhibited cell viability in a dose-dependent manner.
Sulforaphane induces apoptosis in human vestibular schwannoma cells. Human HEI-193 cells 
were used to quantify the effect of SFN on apoptosis using annexin V-propidium iodide (PI) staining and TUNEL 
staining. In annexin V-PI staining assays, the relative strength of fluorescein isothiocyanate (FITC) and PI (FL4) 
fluorescence reflects cell health and is depicted in 4 quadrants (Fig. 2A): 1) dead cells exhibit weak FITC fluo-
rescence and strong PI fluorescence (left upper quadrant, known as quadrant Al1); 2) late apoptotic cells exhibit 
strong FITC and strong PI fluorescence (right upper quadrant, known as quadrant Al2); 3) healthy cells exhibit 
low levels of FITC and PI fluorescence (left lower quadrant, known as quadrant Al3); 4) early apoptotic cells 
exhibit strong FITC and weak PI fluorescence (right lower quadrant, known as quadrant A14). Compared to HEI-
193 cells treated with vehicle control (Fig. 2A(a)), HEI-193 cells treated with 10 μ M SFN (Fig. 2A(b) and 20 μ M 
SFN (Fig. 2A(c)) had significantly higher proportions of apoptotic cells (Al2 + Al4), as summarized in Fig. 2A(d).
Sulforaphane-induced apoptosis in HEI-193 cells was demonstrated further using TUNEL staining in situ, 
which detects DNA fragmentation. A significant increase in both DNA fragmentation and perinuclear apoptotic 
body formation were seen in HEI-193 cells treated with 10 μ M SFN compared to control cells treated with vehicle 
only (Fig. 2B).
Apoptotic assays based on staining characteristics (Fig. 2A) and DNA fragmentation (Fig. 2B) were com-
plemented by measuring proteins involved in apoptosis by Western blot (Fig. 2C). Specifically, we measured 
expression of caspase-9, caspase-3, and caspase-3-mediated poly (ADP-ribose) polymerase (PARP), as well as 
the cleaved forms of these proteins. In HEI-193 cells treated with 20 μ M SFN for 48 h relative to controls, the 
expression of pre-caspase-9 (precursor form) significantly decreased, while the expression of cleaved caspase-9 
increased. Cleavage of caspase-3 was used as a marker of cells undergoing apoptosis, while the observed cleavage 
of PARP was consistent with caspase-mediated apoptosis. Taken together, these data confirm SFN-induced apop-
tosis in HEI-193 cells via induction of caspase activity.
Sulforaphane induces cell cycle arrest. Because arresting the cell cycle can have a therapeutic effect for 
various neoplasms10,12, we studied whether sulforaphane arrested the cell cycle of HEI-193 cells (Fig. 3). SFN 
significantly arrested schwannoma cells in the G2/M phase of the cell cycle in a concentration-dependent manner 
(Fig. 3A). When comparing 0 versus 20 μ M SFN, the proportion of HEI-193 cells in G2/M phase increased from 
15.57 ± 0.79 to 47.68 ± 2.96% (p < 0.01), implying G2/M arrest (Fig. 3B).
Sulforaphane inhibits histone deacetylase activity and increases ERK in schwannoma cells. 
Because sulforphane is a potent inhibitor of histone deacetylase (HDAC) in several malignancies7, we studied 
whether it had a similar effect on non-malignant schwannoma cells. HDAC activity was inhibited by SFN in a 
dose-dependent manner in HEI-193 cells (Fig. 4A). Moreover, expression of acetyl histone H3 was significantly 
increased in a dose-dependent manner, as assessed by Western blot (Fig. 4B). Regulation of the AKT/mTOR sig-
naling kinases and extracellular signal-regulated kinase (ERK) has previously been observed in response to SFN 
treatment in breast cancer, prostate cancer, and hepatoma6,13,14. SFN induced activation of ERK in HEI-193 cells 
but had no effect on AKT/mTOR (Fig. 4C).
Sulforaphane inhibits schwannoma growth in vivo. To examine the effect of SFN on schwannomas 
in vivo, mouse SC4 Nf2−/− Schwann cells were allografted to nude mice. Mice were treated with SFN or vehicle 
control via intraperitoneal administration five times per week for 6 weeks, after which we compared tumor vol-
umes between groups. No statistically significant change in mean body weight between SFN-treated (n = 8 mice) 
and control animals (vehicle only, n = 8 mice) was observed over the course of the study, suggesting that SFN was 
not toxic (Fig. 5A). SFN-treated mice (25 mg/kg) showed a statistically significant inhibition of tumor growth 
at all time points from 16 days after treatment on. At the completion of treatment a 27.2% reduction in tumor 
volume (p < 0.05) was observed compared with the vehicle control group (Fig. 5B). Tumor weight was also sig-
nificantly lower at the completion of treatment, with the SFN group exhibiting a 25.8% reduction in mean tumor 
weight relative to the vehicle control group (p < 0.05; Fig. 5C).
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Discussion
We have shown, for the first time, that a dietary extract, sulforaphane, is therapeutic against human vestibular 
schwannoma cells in vitro and mouse schwannoma cells in vivo. Significant insights into the pathways underlying 
VS pathogenesis have led to a variety of new therapeutic targets for intervention in schwannoma. Targeted molec-
ular therapies for VS using EGFR/ErBb2 (lapatinib), mTOR (everolimus), and VEGF inhibitor (bevacizumab) 
have been examined in patients with NF215–17. However, the cost and toxicity associated with these treatments 
Figure 1. Sulforaphane inhibits proliferation of primary human vestibular schwannoma (VS) cells in 
a dose-dependent manner. (A) Proliferation of primary human VS cells derived from a combination of 3 
different VSs, as measured using bromodeoxyuridine (BrdU) incorporation (red), was inhibited by application 
of sulforaphane (10 μ M) for 48 h. BrdU incorporation was calculated as the percentage of BrdU-labeled 
nuclei relative to total nuclei stained with Hoechst33342. Scale bar = 100 μ M (same scale bar applies to all). 
Bar graph depicts mean ± standard error of mean (SEM, n = 9). ***p < 0.001. (B) Cell viability (measured 
with MTT assay) of human HEI-193 cells and (C) mouse SC4 Nf2−/− Schwann cells incubated with 5–25 μ M 
concentrations of sulforaphane for 48 h. Bar graphs represent mean ± SEM (n = 6).
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may be inappropriate for non-malignant tumors, such as VS. Alternative treatments, based on safe dietary sup-
plements capable of slowing the progression of VS, may represent a more practical approach for many patients. 
For this reason, we have reported three alternative natural products capable of inhibiting the growth of HEI-
193 cells18–20. Furthermore, Spear et al. reported that cucurbitacin D and goyazensolide exhibit anti-proliferative 
Figure 2. Effect of sulforaphane on apoptosis in HEI-193 cells. (A) Cell death quantified by Annexin V-PI 
staining after application of 0 (a), 10 (b), or 20 (c) μ M SFN for 48 h. Apoptotic cells appear in the right upper  
and right lower quadrant. Bar graph (d) depicts mean ± standard error of mean (SEM, n = 6). ***p < 0.001.  
(B) Apoptosis detected by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL). 
Scale bar = 100 μ m (applies to all). (C) Expression of cleaved caspase-3, -9, and poly-ADP ribose polymerase 
(full-length and cleaved bands), detected by Western blot.
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activity in NF2-deficient schwannoma and meningioma cells, though neither has been tested in primary VS cells 
or in in vivo models21.
Recent studies have identified a variety of micronutrients present in fruits and vegetables, including curcumin, 
resveratrol, genistein, diallyl sulfide, S-allyl cysteine, allicin, lycopene, capsaicin, diosgenin, 6-gingerol, ellagic 
acid, ursolic acid, silymarin, anethol, catechins, eugenol, limonene, beta carotene, and SFN, which appear to limit 
tumor growth, suggesting a mechanism by which dietary constituents may exert anti-carcinogenic activity5,22. 
Here, we sought to identify compounds with inhibitory effects on schwannoma cells at doses consistent with their 
natural concentrations. We found that SFN had inhibitory effects on primary human vestibular schwannoma cells 
and a human NF2-derived VS cell line in vitro, as well as on an in vivo allograft model of VS.
HDAC inhibitors are emerging as a new class of antitumor drugs, due to their ability to promote differenti-
ation, induce cell cycle arrest, and trigger apoptosis23,24. HDAC inhibitors have been shown to inhibit multiple 
intracranial tumors both in vitro and in vivo through a variety of mechanisms25,26. Among these, a novel HDAC 
inhibitor, AR42, has shown inhibitory activity against NF2-associated tumors via the induction of apoptosis27,28. 
SFN has also been shown to inhibit HDAC activity in several human cancers, as evidenced by acetylation of his-
tones H3 and H4, two common markers for successful HDAC inhibition9,10. Our data presented here show that 
SFN treatment results in successful upregulation of acetylated histone H3 in VS cells, increased apoptosis, and cell 
cycle arrest, consistent with HDAC inhibition.
Given the complexity of the signaling pathways downstream of merlin/NF2, a number of potential therapeutic 
targets have been proposed3. The MAPK/ERK and AKT-mTOR pathways are two of the major downstream sig-
naling pathways in schwannomas29. Several studies have shown that HDAC inhibitors may suppress these path-
ways in some tumors30,31; specifically, AR42, a novel HDAC inhibitor, has been shown to reduce VS proliferation 
through AKT signaling27. Additionally, it has been reported that SFN inhibits cell proliferation via activation of 
ERK in prostate tumors and hepatomas6,7. Our data support the conclusion that SFN induces activation of ERK, 
without affecting AKT-mTOR in VS cells.
Figure 3. Cell cycle in HEI-193 cells is arrested by sulforaphane treatment. (A) The distribution of cell cycle, 
as determined by propodium iodide labeling, after application of 0 (a), 10 (b), or 20 (c) μ M SFN for 48 h. DNA 
content was analyzed by flow cytometry. (B) Proportion of cells per phase of cell cycle. Data are depicted as 
mean ± standard error of mean (SEM, n = 3). *p < 0.05; **p < 0.01.
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Although dietary agents can be used in their natural forms to inhibit tumor progression, large doses are often 
necessary to achieve significant therapeutic outcomes. While these agents are pharmacologically safe in most 
situations, one of the main concerns is the lack of bioavailability. However, the bioavailability of these compounds 
should not be evaluated in the same manner as synthetic compounds, as many of these agents exhibit biological 
responses at serum concentrations that are otherwise undetectable in vitro5. It is known that dietary intake of 
sulforaphane translates to micromolar concentrations (0.1~10 μ M) of the compound in various cells8, and doses 
required for HDAC inhibition and apoptosis induction appear to be much higher. However, SFN has been shown 
to accumulate in cells and reach to millimolar concentrations8. More trials will be needed to validate the useful-
ness of SFN either alone or in combination for the treatment of VS.
Taken together, the data presented here demonstrate the inhibitory effects of SFN on VS cells in vitro and 
in vivo. To the best of our knowledge, this is the first report showing that SFN exerts antitumor activity against 
Figure 4. Sulforaphane inhibits histone deacetylase (HDAC) and activates ERK 1/2 kinases in human 
HEI-193 cells. (A) SFN inhibits histone deacetylase activity in HEI-193 cells, as measured with a fluorometric 
kit. Boxes represent as mean ± standard error of mean (SEM, n = 6). ***p < 0.001. (B) Acetylation of histones 
H3 and H4, as assessed by Western blot, following application of 0, 10, or 20 μ M SFN for 48 h. (C) Activation of 
ERK, as assessed by western blot, following application of 0, 10, or 20 μ M SFN for 48 h; α -tubulin was used as 
the loading control. P: phosphor forms. T: total forms.
www.nature.com/scientificreports/
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VS through the inhibition of HDAC. SFN may therefore represent a potential chemotherapeutic agent for the 
treatment of VS.
Methods
Chemicals. DL-SFN (≥ 90% High Performance Liquid Chromatography, HPLC) was purchased from Sigma 
Aldrich (St. Louis, MO, USA). A stock solution of DL-SFN (5 mg/mL) was prepared with dimethyl sulfoxide 
(DMSO) and stored at − 20 °C.
Culture of primary human vestibular schwannoma cell and NF2-derived cell line. Using sterile 
technique, freshly harvested human VS tissue was rinsed in phosphate buffered saline (PBS) and dissected in 
culture medium consisting of Dulbecco’s Modified Eagle’s medium with Ham’s F12 mixture (DMEM/F12), 10% 
fetal bovine serum (FBS), 1% penicillin/streptomycin, and 1% GlutaMAX. VS tissue was then dissociated in hya-
luronidase and collagenase (all Life Technologies, Carlsbad, CA, USA) overnight, and cultured for 2–4 weeks, as 
described previously32. Informed consent was obtained from all patients. The study protocols were approved by 
the Human Studies Committee of Massachusetts General Hospital and Massachusetts Eye and Ear Infirmary, and 
conducted in accordance with the Helsinki Declaration.
Figure 5. Sulforaphane decreases tumor volume in vivo. (A) Body weight, (B) tumor volume, and (C) final 
tumor weight in mice receiving sulforaphane (25 mg/kg, n = 8) or vehicle control (n = 8). Data points and bar 
graphs depict mean ± S.D; *p < 0.05, **p < 0.05, ***p < 0.001 compared with vehicle control.
www.nature.com/scientificreports/
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In addition to a primary human VS cell culture, two cell lines were used: 1) HEI-193 cells, an immortalized cell 
line derived from the vestibular schwannoma of a human NF2 patient, and 2) Nf2−/− SC4 cells, a mouse Schwann 
cell line (both gifts from the House Ear Institute, Los Angeles, CA, USA). The cell lines were cultured in DMEM 
supplemented with 10% FBS and 1% penicillin/streptomycin.
Cell proliferation assay: BrdU incorporation. To study proliferation of primary human VS cell lines, 
cells were incubated with 0 (control) or 10 μ M SFN for 48 h, and then treated with 50 mg/mL bromodeoxyuridine 
(BrdU) (Invitrogen, Carlsbad, CA, USA) for 20 h. The cells were fixed, and the nuclear membranes were perme-
abilized with 1% Triton-X for 10 min, followed by 2N hydrochloric acid for 20 min. Primary antibodies against 
BrdU (AbD) (Serotec, Puchheim, Germany) and anti-rat IgG (Life Technologies) were used. Hoechst 33342 dye 
(hereafter abbreviated Hoechst, Invitrogen) were used to stain nuclei. BrdU- and Hoechst-stained nuclei were 
counted in 3–5 fields, and the ratio of BrdU-positive to Hoechst-positive nuclei was used to determine the pro-
liferation rate in vitro.
Cell viability assay. HEI-193 and SC4 cells were seeded in 96-well plates at 5 × 103 and 3 × 103 cells/well, 
respectively. After 24 h, the medium was replaced with serum-free medium and cells were incubated with var-
ious concentration of DL-SFN for 48 h. To quantify cell viability and metabolic activity, a calorimetric MTT 
[3-(4,5-dimethhylthiaoly)-2,5-diphenyltetrazolium bromide] (5 mg/mL) assay was used. Forty μ g/mL of MTT 
solution (Sigma-Aldrich) in PBS was added to each well for 4 h at 37 °C. The culture medium containing MTT 
was then discarded. Visible formazan crystals were dissolved in 100 μ L of DMSO, followed by shaking for 30 min 
at room temperature in the dark. The optical density (OD) was measured at 595 nm using a microplate reader. All 
experiments were repeated at least 3 times.
Apoptosis assay: Annexin V/propidium iodide (PI) staining. Apoptosis was analyzed using an 
Annexin V assay kit (BD Biosciences Pharmingen, San Jose, CA, USA). Briefly, HEI-193 cells were seeded at 
3 × 105 cells/well in 6-well plates. After 24 h, the medium was replaced with serum-free medium and cells were 
incubated with 10–20 μ M of DL-SFN for 48 h. Both floating and attached cells were then collected by trypsiniza-
tion. After centrifugation at 1,300 rpm for 3 min, the cells were washed twice with PBS and incubated in 1 × bind-
ing buffer (10 m HEPES/NaOH (Ph 7.4), 140 mM NaCl, and 2.5 mM CaCl2) containing annexin V-fluorescein 
isothiocyanate (FITC) and propodium iodide (PI) at room temperature for 10 min in the dark. Stained cells were 
then analyzed using a FACScan flow cytometer (Becton, Franklin Lakes, NJ, USA) within 1 h. The data were ana-
lyzed using WinList 5.0 software (Verity Software House, Topsham, ME, USA).
Apoptosis assay in situ: TUNEL assay. Apoptotic cells were detected in situ by utilizing the terminal deox-
ynucleotidyl trasferase-mediated dUTP nick end labeling (TUNEL) assay (Roche Molec Biochemic,Mannheim, 
Germany). HEI-193 cells were seeded on glass coverslips in 12-well plates at 8 × 104 cells/well in DMEM sup-
plemented with 5% FBS. After the monolayers achieved 70–80% confluence, cells were treated with 10–20 μ M 
DL-SFN for 48 h. Cells on coverglass slides were then washed with PBS, fixed in cold 4% paraformaldehyde 
(Bio-Rad, Hercules, CA, USA) for 1 h, and treated 3% H2O2 in methanol for 10 min at room temperature to 
block endogenous peroxidase. After removal of the blocking solution, the cells were permeabilized in PBS-T 
(0.1% Triton X-100) for 5 min on ice, washed twice with PBS, incubated with TUNEL solution for 1 h at 37 °C, 
stained with 5 μ g/mL Hoechst nuclear counterstain for 30 min at room temperature, and visualized by fluores-
cence microscopy.
Cell cycle study. HEI-193 cells were used to study cell cycle arrest caused by SFN. HEI-193 cells were seeded 
in 6-well plates at 5 × 105cells/well. After SFN application for 48 h, the floating cells and attached cells were col-
lected by trypsinization, centrifuged at 1200 rpm for 5 min, fixed with ice-cold 70% ethanol, and stored at 4 °C for 
1 h. Fixed cells were resuspended with PBS containing RNase A (100 ug/ml, Intron, Daejeon, Korea) for 30 min at 
37 °C, and a propodium iodide (PI) solution (20 ug/ml, Invitrogen) was added. Stained cells were analyzed using 
a FACScan flow cytometer (Becton) and WinList 5.0 software(Verity Software House).
HDAC assay. HDAC activity was quantified using the Histone Deacetylase Assay Kit, Fluorometric 
(Sigma-Aldrich) in accordance with the manufacturer’s protocol. Briefly, protein cell lysates were incubated with 
HDAC substrate (0.2 m M) in HDAC assay buffer at 30 °C for 30 min. Reactions were stopped by adding 10 μ L 
developer solution, followed by incubation at room temperature for 10 min. Fluorescence was measured with 
excitation at 355 nm and emission at 460 nm using a fluorescence plate reader (Perkin Elmer, Boston, MA, USA).
Western blot analysis. HEI-193 cells were used to interrogate activation of signaling molecules by Western 
blot. Specifically, HEI-193 cells were seeded in 10 cm dishes at a density of 1 × 106 cells/well (Marienfeld, 
Germany). Cells were allowed to attach overnight in DMEM containing 10% FBS. To starve cells, the medium was 
replaced with medium containing 0.2% FBS. SFN was then added for 48 h. The cells were washed with PBS and 
collected by scraping in lysis buffer (Sigma-Aldrich) containing 7 × protease inhibitor cocktail and 10 × phos-
phatase inhibitor cocktail (Roche, Basel, Switzerland). Cell lysates were centrifuged at 13,000 rpm for 30 min at 
4 °C, and protein concentration was determined using a lowry assay (Bio-Rad). Proteins (20 μ g) were separated by 
SDS-polyacrylamide gel electrophoresis on a 6–15% gel, and transferred to PVDF membranes (EMD Millipore, 
Billerica, MA, USA). The membranes were blocked with 5% skim milk in TBS-T (0.1% Tween 20) at room tem-
perature for 1 h, followed by incubation with primary antibodies against caspase-3 (Cell Signaling Technology, 
Inc., Danvers, MA, USA), caspase-9 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), acetylated histone 
H3 (EMD Millipore), acetylated histone H4 (EMD Millipore), p-AKT (Santa Cruz), AKT, p-mTOR, mTOR, 
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p-ERK, ERK (all from Cell Signaling Technology), and tubulin (EMD Millipore) overnight at 4 °C. Membranes 
were then washed in TBS-T, and incubated in horseradish peroxidase-conjugated goat anti-rabbit or goat 
anti-mouse antibodies, as appropriate, for 2 h at room temperature. Protein bands were detected by an ECL Plus 
Kit (Bio-Rad).
In vivo tumorigenesis. Six-week-old female BALB/c nude mice (Nara Biotech Co., Seoul, Korea) were 
maintained under specific pathogen-free conditions and fed verified mouse chow. To cultivate tumors, SC4 
Nf2−/− Schwann cells were detached by trypsinization, collected in DMEM medium containing 10% FBS, and 
resuspended at a density of 3.4 × 105 cells/mL in serum-free medium. A total volume of 0.3 mL (containing 
1 × 105 SC4 cells) was injected into the axillary region between the shoulder and chest wall. SFN (25 mg/kg) 
or an equal volume of DMSO (control group) was administered intraperitoneally 5 times per week for 6weeks. 
Each group consisted of eight mice. The tumor growth was evaluated using a caliper and tumor volume was 
estimated using the following formula: length (mm) × width (mm) × height (mm)/2. On the day after the final 
treatment, the animals were sacrificed, the solid tumors excised, and the weight of the tumors was measured. All 
animal work was performed in accordance with a protocol approved by the Institutional Animal Care and Use 
Committee of Korea Research Institute of Bioscience and Biotechnology.
Statistical analysis. All data are presented as the mean ± standard error of mean (SEM). The independent 
t-test or one-way analysis of variance (ANOVA) with posthoc comparison using Bonferroni’s correction was 
employed for statistical analyses. The significance level was set at corrected p < 0.05. SPSS (version 14.0; SPSS, 
Inc, Chicago, Ill, USA) and R (version 3.1.3, The R Foundation for Statistical Computing, Vienna, Austria) were 
used to complete all analyses.
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